Biotech Market Research – Different Approach To Stay Ahead Of Your Competitor

(Albany, US) Traditional method of toxicity and drug safety studies is expensive, has a low success rate, and is resource- and time-consuming. To overcome these challenges, pharmaceutical companies are increasingly adopting high-content screening (HCS) cell-based assays for identifying the effects of toxicity in drug development studies (cell-based imaging enables the monitoring of drug toxicity mechanisms, such as oxidative stress, micronuclei, mitochondrial dysfunction, steatosis, and apoptosis). DelveInsight is the world's leading independent provider of strategic market intelligence solutions. Our market intelligence services are designed to connect your organization’s goals with global opportunities. RFP to know more about  DelveInsight’s competitive intelligence for pharma companies . Market & Competitive Assessment Business Problem: A large Asian conglomerate was working to develop their asset portfolio in Cell Imaging and Analysis, and was interested to assess t

  ESMO Abstracts: CheckMate 067 Results at ESMO 2020 Abstract No :  Abstract: #1105P Indication :  Melanoma Intervention :  Nivolumab Company :  Bristol-Myers Squibb Technology :  PD-1/PD-L1 inhibitor Mixture models adequately captured the survival plateaus in CheckMate 067 and suggested a higher proportion of LTSs with NIVO and NIVO+IPI than with IPI. These methods may be used in the indirect estimation of auxiliary outcomes, such as time to subsequent treatment and impact of subsequent treatments on LTSs. Read More: https://www.delveinsight.com/esmo-conference-2020/article/checkmate-067-NCT01844505-esmo-2020   CheckMate -577 Results at ESMO 2020 Abstract No :  Abstract: #LBA9 Indication :  Esophageal Cancer, Gastroesophageal junction cancer Intervention :  Nivolumab Company :  Bristol-Myers Squibb Technology :  PD-1/PD-L1 inhibitor Adjuvant nivolumab is the first therapeutic to provide a statistically significant and clinically meaningful improvem

ASCO Abstracts 2020   ASCO: Results of IMpower110 study Abstract No : 9594 Abstract Type : Poster Session Indication : Non-Small Cell Lung Cancer Intervention : Atezolizumab (atezo) vs chemotherapy Company : F. Hoffmann-La Roche, Ltd Technology : Monoclonal antibody QLQ-C30 and QLQ-LC13 completion rates were high at BL and most study visits. TTD of lung cancer-related symptoms was similar in both arms, indicating pts’ low BL symptom burden was maintained for a similar duration. Pts receiving atezo vs chemo sustained numerical improvements in physical function and no worsening in lung cancer-related symptoms. Read More: https://www.delveinsight.com/asco-conference/article/NCT02409342   ASCO: Results from CARTITUDE-1 Abstract No : 8505 Abstract Type : Oral Abstract Session Indication : Multiple Myeloma Intervention : JNJ-4528 Company : Janssen Research & Development, LLC Technology : CAR T Cell Therapy JNJ-4528 treatment led to responses in all

  Bile Duct Neoplasm Market DelveInsight's " Bile Duct Neoplasms Market Insights, Epidemiology, and Market Forecast-2030"  report delivers an in-depth understanding of the Bile Duct Neoplasms , historical and forecasted epidemiology as well as the Bile Duct Neoplasms market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Bile Duct Neoplasm Companies : ·          Agios Pharmaceuticals ·          AstraZeneca ·          Merck/EMD Serono ·          QED Therapeutics ·          Nucana ·          Lexicon Pharmaceutical ·          And Many Others View Report: https://www.delveinsight.com/report-store/bile-duct-neoplasms-market   Dermatomycoses Market DelveInsight's "Dermatomycoses Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Dermatomycoses , historical and forecasted epidemiology as well as the Dermatomycoses market trends in the Un

  Post-Surgical Pain Market        The   Post-Surgical Pain market report provides current treatment practices, emerging drugs, Post-Surgical Pain market share of the individual therapies, current and forecasted Post-Surgical Pain market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Post-Surgical Pain treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. Post-Surgical Pain Drugs covered 1. Olinvo (Oliceridine injection or TRV130) 2. HTX011 3. CR845/Difelikefalin 4. NTM001 5. PF05089771 And many others The key players in Post-Surgical Pain market are: 1. Trevena 2. Heron Therapeutics 3. Cara Therapeutics 4. Neumentum Pharmaceuticals 5. Pfizer And many others View Report: https://www.delveinsight.com/report-store/post-surgical-pain-market   Idiopathic Membranous Nephropathy Market The  

  ASCO Abstracts ASCO: Lisocabtagene maraleucel ( liso-cel ) Abstract No :  8040 Indication :   Non-Hodgkin's Lymphoma  (aggressive) Intervention :  Lisocabtagene maraleucel Company :  Juno Therapeutics, a Bristol-Myers Squibb company Technology :  CAR T Cell therapy These interim data suggest that elderly and/or comorbid pts with R/R aggressive large B-cell NHL, who are not eligible for high-dose chemotherapy and HSCT, can receive 2L liso-cel with similar safety and efficacy to 3L+ pts as previously reported (Abramson, ASH 2019 #241). Updated data with longer follow-up will be presented. Read More: https://www.delveinsight.com/asco-conference/article/lisocabtagene-maraleucel   ESMO Abstracts ADAURA trial results at ESMO ADAURA  is a randomized, double-blinded, global, placebo-controlled phase III trial in the adjuvant treatment of 682 patients with stage IB, II, IIIA EGFRm  NSCLC  resulting in the complete tumor resection and adjuvant chemotherapy as indi